32 results about "Viral Components" patented technology

The invention provides a virus infection detection and identification technology based on metagenomics. The virus infection detection and identification technology based on the metagenomics comprises the four portions of sample preparation, high-throughput sequencing, bioinformatic analysis and result re-checking. In the sample preparation portion, viral nucleic acid is effectively extracted or enriched from detection samples according to the requirements of the virus infection detection and identification technology based on the metagenomics and characteristics of different types of detection samples, and a nucleic acid library which can be used for a next-generation sequencing instrument is established. In the high-throughput sequencing portion, the nucleic acid library established in the sample preparation step is sequenced so to obtain sufficient high-quality nucleic acid sequence information. In the bioinformatic analysis portion, a large number of high-quality nucleic acid sequences obtained in the high-throughput sequencing step is analyzed to further obtain viral component information prompted by the nucleic acid of the samples. In the result re-checking portion, a bioinformatic analysis result and other information, such as technical contrast, are integrated to perform comprehensive study and judgment, finally alternative infection virus is determined, and other technologies, such as PCR, are utilized to perform re-checking.

Disclosed herein are compositions and methods for imaging nerve cells. The composition comprises a fluorescent dye; and a viral component selected from a neurotropic, replication-defective virus, a viral protein of a neurotropic virus, and a capsid of a neurotropic virus. Although the fluorescent dye in itself cannot penetrate nerve cells, the fluorescent dye is bound to the viral component to form a dye / viral component complex that is capable of penetrating nerve cells.

The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and / or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.

A composition for in vivo transfection of vertebrate male germ cells comprises a nucleic acid or transgene, and a gene delivery system, and optionally a protective internalizing agent, such as an endosomal lytic agent, a virus or a viral component, which is internalized by cells along with the transgene and which enhances gene transfer through the cytoplasm to the nucleus of the male germ cell. A pharmaceutical preparation and a transfer kit utilize the composition. A method for introducing a polynucleotide into vertebrate male germ cells comprises the administration of the composition to a vertebrate. A method for isolating or selecting transfected cells utilizes a reporter gene, and a method for administering transfected male germ cells utilizes male germ cells which have been transfected in vitro.

The present invention provides a closed system to propagate virus-infected cells without the effect of shear force, while providing quicker access to nutrients than is available conventionally. This system design allows for a high density of infected cell growth to increase the virus yields and to maintain homogeneity of the contents of the main container. The system further provides a nuclease to degrade the cellular DNA prior for purification of the virus or viral components. As the system is designed for maximum containment at low risk, the live virus can be a hazardous virus such as a Bio-safety Level 3 (BSL 3), BSL 4 or BSL5 virus.

Therapeutic viral formulations having enhanced storage stability are described. The formulations comprise a viral vector in addition to one or more of an aqueous cosolvent, a reversible viral-encoded protease inhibitor and a mild reducing agent or other agent that prevents specific degradation of viral components.

The invention provides a method of reducing viral infectivity in a sample compnsing contacting the sample with a earner matrix wherein lipids are attached to the carrier matrix, and wherein at least one virus-specific agent is attached to the lipids The virus-specific agent is capable of binding to at least one viral component The virus specific agent may be a receptor The earner matrix may be a silica particle, which may be coated with a lipid bilayer The invention further provides a method of inactivating a virus comprising contacting the virus with a earner matrix wherein lipids are attached to the earner matrix, and wherein at least one receptor is attached to the lipids, binding the receptor to at least one viral receptor-binding protein, and activating at least one viral fusion protein, wherein activation inactivates the virus, and releases the virus from the earner matrix

An injectable composition, capable of preventing or controlling parasitic, viral, or bacterial infections or diseases, for example scours, in pregnant cows and viral infections or diseases in neonatal calves by parenterally administering to each cow in a herd of pregnant cows, a dose of a combination composition comprising: (a) at least one inactivated viral component derived from rotavirus and / or coronavirus; (b) a macrocyclic lactone active compound; and (c) a pharmaceutically acceptable parenteral carrier and preservative. The injectable compositions which include eprinomectin result in extremely low milk residues.

An adjuvant composition comprises a Th1-activating alkaloid, optionally further comprising an auxiliary adjuvant selected from a type 2 adjuvant (e.g. alum and / or MF59), a type 1 adjuvant and / or a balanced adjuvant. Vaccines comprising the adjuvant composition include nucleic acid(s) which encode one or more antigenic protein(s); protein(s) or peptide(s); glycoprotein(s); polysaccharide(s) (e.g. carbohydrate(s)); fusion protein(s); lipid(s); glycolipid(s); peptide mimic(s) of polysaccharides carbohydrate(s) and a protein(s) in admixture; carbohydrate-protein conjugate(s); cells or extracts thereof; dead or attenuated cells or extracts thereof; tumour cells or extracts thereof; viral particles (e.g. attenuated viral particles or viral components); allergen(s) mixtures thereof.

The invention relates to plants and plant cells which have a transient or permanent virus resistance as a result of modulation of the gene expression and / or binding behavior of vegetable DnaJ-like proteins. The invention also relates to methods for the production of transgenic plants with increased virus resistance, wherein the expression of vegetable DnaJ-like proteins which interact with viral components is substantially prevented by silencing the DnaJ-like proteins. The invention further relates to methods for the production of transgenic plants with increased virus resistance, wherein the interaction of viral components with vegetable DnaJ-like proteins is substantially prevented by expression of dominant-negative mutants of the DnaJ-like proteins, by antibodies against DnaJ-like proteins or by specific inhibitors.

A sample is divided into a series of aliquots with the aliquots being subjected to at least two successive parallel separation steps in order to resolve protein or viral components thereof. The separation steps are performed not only on a sample but subsamples each containing a prelabeled tag to afford comparisons between subsamples. The parallel separation is amenable to high throughput and automation.

The invention provides a new application of miRNA-484, a pharmaceutical composition containing miRNA-484 and the application thereof. The use of the miRNA-484 in the preparation of medicines for preventing or treating heart disease, the pharmaceutical composition, the pharmaceutical composition is composed of an effective dose of miRNA-484 pharmaceutically acceptable carrier, virus or auxiliary material. miRNA-484 has a protective effect on the heart by inhibiting cardiomyocyte apoptosis, and miRNA-484 has potential preventive and therapeutic value for many heart diseases.

The present invention relates to a method for prevention and / or reduction of aggregation of viral components.

A novel virus, the Chris-like virus, has been identified and characterised. Sequences derived from a new paramyxovirus, Chris-like virus (CV), are provided. These sequences encode viral proteins with similarity to recognized viral proteins in other known and characterized paramyxoviruses. The CV viral sequences and the polypeptides encoded therein are useful for the detection, immunological protection and therapy of CV. The sequences provided by the invention are also useful for the isolation and characterization of CV, for the propagation of CV or its viral components in cells or tissue culture, for the generation of immunogenic polypeptides and vaccines, and for the screening and identification of antiviral agents for CV.

The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.

The present invention provides nucleic acid constructs, expression systems, and methods relating to the regulation of gene expression. The invention may be applied to regulate the expression of any coding sequence of interest, including those coding for viral components necessary for the packaging of viral particles.

Disclosed are methods and compositions for identifying viral-specific polynucleotide sequences in a biological sample, and particularly in samples of veterinary origin. Also disclosed are oligonucleotide primer pairs, as well as labeled oligonucleotide detection probes useful in detecting the presence of one or more particular species, strains, types, or subtypes of one or more mammalian pathogens of viral origin, as well as systems, diagnostic kits and articles of manufacture comprising virus-specific primers and labeled detection probes, including those useful in identifying viral components of a multivalent vaccine, and quantitating the potency of particular attenuated, live viruses that comprise a livestock vaccine. In certain embodiments, real-time, quantitative PCR methods have been utilized to identify and distinguish between the three known genetic subtypes of bovine viral diarrhea viruses (BVDV-1a, BVDV-1b, and BVDV-2) in a multivalent bovid shipping fever vaccine.

A non-invasive, transcutaneous, real-time viral detection device that is configured for self-administration, e.g., at a user's home. In one embodiment, and after positioning the device relative to the human body part (e.g., the user's finger), light sources in the device are activated (excited), and resulting data captured. In particular, a set of Raman spectra are collected from a configured set of emitters and detectors in the device and delivered to a nearby receiver, preferably wirelessly. The receiver filters and de-convolves the Raman spectra producing a data set representative of the constituent elements in the user's tissue of interest. The data set is applied against a statistical classifier, e.g., a neural network that has been trained to recognize and distinguish the absence or presence of viral components, e.g., C-19, or its associated blood-borne acute phase reactants. The classifier outputs an appropriate indicator, preferably in real-time, providing the user with an immediate indication of whether C-19 (or other virus of interest) is present.

The present disclosure provides a method of isolating and preparing live African swine fever (ASF) virus (ASFV) and ASFV vaccines comprising intact ASF virions, viral components, and / or immunosuppressive protein factors. The ASFV vaccine may be used to immunize pigs and wild boars, or may be used to immunize species other than pigs or wild boars, such as poultry, cattle, goats, rabbits, donkeys, or horses, to produce polyclonal immunoglobulins with broad spectrum specificity for ASFV. The ASFV-specific immunoglobulins may then be extracted and purified. The ASFV-specific immunoglobulins may provide acute treatment for ASF-infected pigs or wild boars, or prophylactic treatment for pigs or wild boars at risk of ASF, for example, those may have been exposed to ASFV or ASFV infection.

Disclosed are methods and compositions for identifying viral-specific polynucleotide sequences in a biological sample, and particularly in samples of veterinary origin. Also disclosed are oligonucleotide primer pairs, as well as labeled oligonucleotide detection probes useful in detecting the presence of one or more particular species, strains, types, or subtypes of one or more mammalian pathogens of viral origin, as well as systems, diagnostic kits and articles of manufacture comprising virus-specific primers and labeled detection probes, including those useful in identifying viral components of a multivalent vaccine, and quantitating the potency of particular attenuated, live viruses that comprise a livestock vaccine. In certain embodiments, real-time, quantitative PCR methods have been utilized to identify and distinguish between the three known genetic subtypes of bovine viral diarrhea viruses (BVDV-1a, BVDV-1b, and BVDV-2) in a multivalent bovid shipping fever vaccine.